UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 303

Sortiert nach

Tamoxifen and pregnancy: an absolute contraindication?

Breast cancer research and treatment, 2019-05, Vol.175 (1), p.17-25

2019

Volltextzugriff (PDF)

Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial)

Gynecologic oncology, 2022-05, Vol.165 (2), p.223-229

2022

Volltextzugriff (PDF)

Surgical lymph node assessment in mucinous ovarian carcinoma staging: a systematic review and meta‐analysis

BJOG : an international journal of obstetrics and gynaecology, 2017-02, Vol.124 (3), p.370-378

2017

Volltextzugriff (PDF)

Interval between debulking surgery and adjuvant chemotherapy is associated with overall survival in patients with advanced ovarian cancer

Gynecologic oncology, 2018-09, Vol.150 (3), p.446-450

2018

Volltextzugriff (PDF)

Plasmon-induced demagnetization and magnetic switching in nickel nanoparticle arrays

Applied physics letters, 2018-02, Vol.112 (7)

2018

Volltextzugriff (PDF)

Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors

Annals of oncology, 2011-02, Vol.22 (2), p.431-437

2011

Volltextzugriff (PDF)

Prospective practice survey of management of cetuximab-related skin reactions

Supportive care in cancer, 2021-07, Vol.29 (7), p.3497-3506

2021

Volltextzugriff (PDF)

Phase II study on paclitaxel in patients with recurrent, metastatic or locally advanced vulvar cancer not amenable to surgery or radiotherapy: a study of the EORTC-GCG (European Organisation for Research and Treatment of Cancer—Gynaecological Cancer Group)

Annals of oncology, 2009-09, Vol.20 (9), p.1511-1516

2009

Volltextzugriff (PDF)

Patient‐reported symptoms and stepwise symptom management in patients on epidermal growth factor inhibitors: A retrospective, descriptive cohort study

European journal of cancer care, 2018-03, Vol.27 (2), p.e12800-n/a

2018

Volltextzugriff (PDF)

Patient-reported outcome measures in a pharmacokinetic study with sunitinib, a prospective cohort study

Supportive care in cancer, 2018-08, Vol.26 (8), p.2641-2650

2018

Volltextzugriff (PDF)

Phase I/II study of single agent MCLA-128, a full length IgG1 bispecific antibody targeting the HER3 pathway: Overall safety at the recommended phase II dose (R2PD) and preliminary activity in HER2+ metastatic gastric/gastroesophageal junction cancer (GC/GEJ)

Annals of oncology, 2018-10, Vol.29, p.viii223-viii224

2018

Volltextzugriff (PDF)

Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment

Cancer chemotherapy and pharmacology, 2012-12, Vol.70 (6), p.823-832

2012

Volltextzugriff (PDF)

Phase I study of oral CP-4126, a gemcitabine derivative, in patients with advanced solid tumors

Investigational new drugs, 2013-08, Vol.31 (4), p.959-966

2013

Volltextzugriff (PDF)

Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours

British journal of cancer, 2015-09, Vol.113 (5), p.706-715

2015

Volltextzugriff (PDF)

Intraperitoneal treatment for advanced ovarian cancer, the Dutch experience. What did we learn?

Netherlands journal of medicine, 2020-12, Vol.78 (6), p.349-356

2020

Volltextzugriff (PDF)

Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors

Annals of oncology, 2011-11, Vol.22 (11), p.2508-2515

2011

Volltextzugriff (PDF)

A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors

Investigational new drugs, 2016-06, Vol.34 (3), p.329-337

2016

Volltextzugriff (PDF)

Structure and Dynamics of Confined Alcohol–Water Mixtures

ACS nano, 2016-07, Vol.10 (7), p.6762-6768

2016

Volltextzugriff (PDF)

Symptoms from treatment with sunitinib or sorafenib: a multicenter explorative cohort study to explore the influence of patient-reported outcomes on therapy decisions

Supportive care in cancer, 2014-09, Vol.22 (9), p.2371-2380

2014

Volltextzugriff (PDF)

ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

Annals of oncology, 2019-05, Vol.30 (5), p.672-705

2019

Volltextzugriff (PDF)

Pediatric Outcome after Maternal Cancer Diagnosed during Pregnancy

The New England journal of medicine, 2015-11, Vol.373 (19), p.1824-1834

2015

Volltextzugriff (PDF)

Specialized Care and Survival of Ovarian Cancer Patients in The Netherlands: Nationwide Cohort Study

JNCI : Journal of the National Cancer Institute, 2008-03, Vol.100 (6), p.399-406

2008

Volltextzugriff (PDF)

Symptoms and adverse effects with chemotherapy ± bevacizumab for platinum-resistant recurrent ovarian cancer: Analysis of the phase III AURELIA trial

Gynecologic oncology, 2013-07, Vol.130 (1), p.e3-e3

2013

Volltextzugriff (PDF)

ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

International journal of gynecological cancer, 2019-05, Vol.29 (4), p.728-760

2019

Volltextzugriff (PDF)

Long-term neurocognitive, psychosocial, and physical outcomes after prenatal exposure to radiotherapy: a multicentre cohort study of the International Network on Cancer, Infertility, and Pregnancy

The lancet child & adolescent health, 2024-06, Vol.8 (6), p.433-442

2024

Volltextzugriff (PDF)

1 – 25 von 303

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(275)
Mit Volltextzugriff
(258)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Tamoxifen and pregnancy: an absolute contraindication?

Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial)

Surgical lymph node assessment in mucinous ovarian carcinoma staging: a systematic review and meta‐analysis

Interval between debulking surgery and adjuvant chemotherapy is associated with overall survival in patients with advanced ovarian cancer

Plasmon-induced demagnetization and magnetic switching in nickel nanoparticle arrays

Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors

Prospective practice survey of management of cetuximab-related skin reactions

Phase II study on paclitaxel in patients with recurrent, metastatic or locally advanced vulvar cancer not amenable to surgery or radiotherapy: a study of the EORTC-GCG (European Organisation for Research and Treatment of Cancer—Gynaecological Cancer Group)

Patient‐reported symptoms and stepwise symptom management in patients on epidermal growth factor inhibitors: A retrospective, descriptive cohort study

Patient-reported outcome measures in a pharmacokinetic study with sunitinib, a prospective cohort study

Phase I/II study of single agent MCLA-128, a full length IgG1 bispecific antibody targeting the HER3 pathway: Overall safety at the recommended phase II dose (R2PD) and preliminary activity in HER2+ metastatic gastric/gastroesophageal junction cancer (GC/GEJ)

Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment

Phase I study of oral CP-4126, a gemcitabine derivative, in patients with advanced solid tumors

Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours

Intraperitoneal treatment for advanced ovarian cancer, the Dutch experience. What did we learn?

Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors

A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors

Structure and Dynamics of Confined Alcohol–Water Mixtures

Symptoms from treatment with sunitinib or sorafenib: a multicenter explorative cohort study to explore the influence of patient-reported outcomes on therapy decisions

ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

Pediatric Outcome after Maternal Cancer Diagnosed during Pregnancy

Specialized Care and Survival of Ovarian Cancer Patients in The Netherlands: Nationwide Cohort Study

Symptoms and adverse effects with chemotherapy ± bevacizumab for platinum-resistant recurrent ovarian cancer: Analysis of the phase III AURELIA trial

ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

Long-term neurocognitive, psychosocial, and physical outcomes after prenatal exposure to radiotherapy: a multicentre cohort study of the International Network on Cancer, Infertility, and Pregnancy

Suchergebnisse filtern